These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 8137263)
41. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer. Catalano T; Curia MC; Aceto G; Verginelli F; Cascinu S; Cama A; Mariani-Costantini R; Teti D; Battista P Oncol Rep; 2005 Sep; 14(3):625-31. PubMed ID: 16077965 [TBL] [Abstract][Full Text] [Related]
42. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708 [TBL] [Abstract][Full Text] [Related]
43. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis. Chang KW; Sarraj S; Lin SC; Tsai PI; Solt D Carcinogenesis; 2000 Jul; 21(7):1441-51. PubMed ID: 10874024 [TBL] [Abstract][Full Text] [Related]
44. [Detection of K-ras gene mutations in DNA extracted from the plasma of patients with pancreatic cancer]. Feng D; Han T; Jiang Y; Yuan Z; Wang X; Jiang Z; Zhang S Zhonghua Wai Ke Za Zhi; 2000 Oct; 38(10):767-70. PubMed ID: 11832160 [TBL] [Abstract][Full Text] [Related]
45. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Adsay NV; Basturk O; Cheng JD; Andea AA Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479 [TBL] [Abstract][Full Text] [Related]
46. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer. Kang JH; Kim SJ; Noh DY; Choe KJ; Lee ES; Kang HS J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068 [TBL] [Abstract][Full Text] [Related]
47. Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients. Soliman AS; Bondy M; Webb CR; Schottenfeld D; Bonner J; El-Ghawalby N; Soultan A; Abdel-Wahab M; Fathy O; Ebidi G; Zhang Q; Greenson JK; Abbruzzese JL; Hamilton SR Int J Cancer; 2006 Sep; 119(6):1455-61. PubMed ID: 16619252 [TBL] [Abstract][Full Text] [Related]
55. Pancreatic carcinomas of acinar and mixed acinar/ductal phenotypes in Ela-1-myc transgenic mice do not contain c-K-ras mutations. Schaeffer BK; Terhune PG; Longnecker DS Am J Pathol; 1994 Sep; 145(3):696-701. PubMed ID: 8080049 [TBL] [Abstract][Full Text] [Related]
56. Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. Shaw P; Tardy S; Benito E; Obrador A; Costa J Oncogene; 1991 Nov; 6(11):2121-8. PubMed ID: 1945416 [TBL] [Abstract][Full Text] [Related]
57. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Z'graggen K; Rivera JA; Compton CC; Pins M; Werner J; Fernández-del Castillo C; Rattner DW; Lewandrowski KB; Rustgi AK; Warshaw AL Ann Surg; 1997 Oct; 226(4):491-8; discussion 498-500. PubMed ID: 9351717 [TBL] [Abstract][Full Text] [Related]